Compositions of buprenorphine and μ antagonists

US8822488B2 · kind B2 · utility

Assignee

• Alkermes Pharma Ireland Limited · IE

Inventors

• Daniel R. Deaver · Franklin, US
• Elliot Ehrich · Lincoln, US

Key dates

• Filing date: Dec 14, 2012
• Grant date: Sep 2, 2014
• Expiry date: Dec 14, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a composition comprising buprenorphine and a μ opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein;